Last 48 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Corcept Therapeutics Incorporated's quarterly P/E stands at 43.5x, down 10.2% year-over-year — suggesting improving earnings relative to price. EV/EBITDA has expanded 259.1% YoY to 204.1x, reflecting rising market expectations or slowing EBITDA growth.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 43.54 | 43.50 | 129.86 | 63.28 | 167.97 | 48.45 | 28.22 | 25.38 | 25.19 | 29.00 | 24.33 | 22.25 | 38.68 |
| — | -10.2% | +360.2% | +149.3% | +566.8% | +67.1% | +16.0% | +14.1% | -34.9% | -20.0% | +13.8% | -10.2% | +37.4% | |
| P/S Ratio | 4.97 | 5.16 | 11.95 | 11.37 | 21.76 | 8.20 | 7.21 | 5.52 | 4.71 | 6.65 | 6.12 | 5.18 | 5.92 |
| — | -37.1% | +65.8% | +106.1% | +361.6% | +23.4% | +17.7% | +6.5% | -20.3% | +16.0% | -16.7% | -22.0% | -14.4% | |
| P/B Ratio | 6.61 | 6.44 | 15.71 | 13.91 | 20.03 | 8.78 | 8.24 | 6.06 | 5.05 | 7.11 | 6.56 | 5.78 | 4.72 |
| — | -26.7% | +90.7% | +129.5% | +296.3% | +23.6% | +25.7% | +4.8% | +7.1% | +51.0% | +3.8% | -6.8% | -25.7% | |
| P/FCF | 26.68 | 27.16 | 45.55 | 50.38 | 681.02 | 25.22 | 18.23 | 22.17 | 29.14 | 152.95 | 14.31 | 14.45 | 24.08 |
| — | +7.7% | +149.9% | +127.3% | +2237.3% | -83.5% | +27.3% | +53.4% | +21.0% | +763.8% | -36.2% | -62.0% | +31.0% | |
| EV / EBITDA | 78.58 | 204.09 | 229.24 | 80.57 | 876.92 | 56.84 | 27.24 | 24.35 | 22.11 | 26.88 | 23.16 | 18.96 | 36.33 |
| — | +259.1% | +741.4% | +230.9% | +3866.9% | +111.5% | +17.6% | +28.4% | -39.2% | +8.8% | +2.9% | -10.2% | +58.3% | |
| EV / EBIT | 81.89 | 48.00 | 160.86 | 81.98 | 995.52 | 57.88 | 27.54 | 20.98 | 22.20 | 27.36 | 23.38 | 19.15 | 37.04 |
| — | -17.1% | +484.2% | +290.7% | +4385.2% | +111.5% | +17.8% | +9.6% | -40.1% | +7.2% | +1.5% | -11.2% | +56.7% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Corcept Therapeutics Incorporated's operating margin was 2.2% in Q4 2025, down 2.7 pp QoQ and down 11.7 pp YoY. This marks the 3rd consecutive quarter of margin compression, signaling a persistent pressure on profitability that investors should monitor. The trailing four-quarter average of 5.8% exceeds the current quarter, suggesting the latest result may reflect seasonal weakness or a one-off headwind.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 98.3% | 98.7% | 97.8% | 98.2% | 98.5% | 98.4% | 98.4% | 98.5% | 98.3% | 98.6% | 98.7% | 98.7% | 98.7% |
| — | +0.4% | -0.7% | -0.2% | +0.2% | -0.2% | -0.2% | -0.2% | -0.4% | +0.1% | -0.0% | -0.1% | +0.0% | |
| Operating Margin | 5.9% | 2.2% | 4.9% | 13.7% | 2.2% | 13.9% | 25.5% | 21.7% | 20.1% | 23.4% | 25.2% | 25.1% | 14.1% |
| — | -84.0% | -80.7% | -36.9% | -89.2% | -40.6% | +1.2% | -13.5% | +42.9% | +7.1% | -19.6% | -17.3% | -50.8% | |
| Net Margin | 13.1% | 12.0% | 9.3% | 18.1% | 12.9% | 16.7% | 25.6% | 21.7% | 18.9% | 23.2% | 25.4% | 23.4% | 15.0% |
| — | -28.1% | -63.5% | -16.6% | -31.8% | -27.9% | +0.8% | -7.4% | +25.8% | +43.8% | -25.4% | -11.8% | -38.2% |
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 15.0% | 3.8% | 3.1% | 5.3% | 3.0% | 4.6% | 7.6% | 6.2% | 5.3% | 6.5% | 7.1% | 5.8% | 3.1% |
| — | -17.7% | -59.6% | -14.1% | -43.5% | -28.8% | +6.4% | +7.2% | +71.0% | +90.2% | -6.0% | -10.2% | -47.1% | |
| ROA | 11.9% | 2.9% | 2.4% | 4.3% | 2.4% | 3.7% | 6.2% | 5.2% | 4.3% | 5.2% | 5.6% | 4.8% | 2.6% |
| — | -21.8% | -61.8% | -17.6% | -44.7% | -27.5% | +11.1% | +7.5% | +64.4% | +73.5% | -16.5% | -15.2% | -48.3% | |
| ROIC | 6.2% | 0.6% | 1.5% | 3.5% | 0.4% | 3.6% | 7.1% | 6.1% | 5.8% | 6.6% | 7.8% | 9.2% | 3.3% |
| — | -81.9% | -79.6% | -42.7% | -92.3% | -46.1% | -8.7% | -33.8% | +72.1% | +68.1% | +35.8% | +48.7% | -46.1% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Corcept Therapeutics Incorporated's Debt/EBITDA ratio is 1.2x, up from 0.6x last quarter — comfortably within a safe range. The current ratio has weakened 12.7% YoY to 2.92x, tightening the short-term liquidity position.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| — | -7.6% | -5.3% | +9.3% | +7096.4% | +3324.8% | +2082.8% | +1250.6% | -87.2% | -86.9% | -86.5% | -86.2% | -84.3% | |
| Debt / EBITDA | 0.13 | 1.23 | 0.59 | 0.24 | 1.76 | 0.27 | 0.14 | 0.16 | 0.00 | 0.00 | 0.01 | 0.01 | 0.04 |
| — | +355.8% | +312.2% | +53.9% | +68586.9% | +5658.1% | +1916.4% | +1491.4% | -93.2% | -90.5% | -86.3% | -85.9% | -62.8% | |
| Current Ratio | 2.92 | 2.92 | 3.14 | 3.06 | 3.07 | 3.35 | 3.70 | 5.57 | 5.18 | 4.39 | 3.54 | 4.65 | 6.77 |
| — | -12.7% | -15.1% | -45.0% | -40.8% | -23.7% | +4.5% | +19.8% | -23.5% | -36.3% | -58.5% | -45.6% | -0.2% | |
| Quick Ratio | 2.85 | 2.85 | 3.07 | 2.98 | 2.96 | 3.26 | 3.64 | 5.48 | 5.10 | 4.31 | 3.48 | 4.57 | 6.69 |
| — | -12.8% | -15.6% | -45.7% | -41.9% | -24.4% | +4.5% | +19.9% | -23.7% | -36.6% | -58.6% | -45.7% | -0.1% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonCorcept Therapeutics Incorporated's current P/E is 43.5x. The average P/E over the last 4 quarters is 101.2x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Corcept Therapeutics Incorporated's current operating margin is 5.9%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Corcept Therapeutics Incorporated's business trajectory between earnings reports.